TNBC-Merit (#622)
Laufzeit: 01.01.2016 - 31.12.2016
imported
Kurzfassung
First-in-human clinical study with RNA-immunotherapy combination of IVAC-W-bre1-uID and IVAC_M_uID for individualized tumour therapy in triple negative breast cancer patients
